Cell & Gene Therapy CEO
Date: Location: Cost:
September 25, 2017 Four Seasons Boston
200 Boylston Street
Boston, MA 02116
(617) 338-4400
Location >

Starting at $1950

 

Dress Code:
Business Attire

Register

Cell & Gene Therapy CEO - September 25 - DRAFT

Speakers and Co-Hosts Include: George Church, Professor of Genetics, Harvard Medical School; Nick ColangeloCEO, Vericel; John CoxCEO, Bioverativ; Olivier Danos,  CSO, Regenxbio; John DawsonCEO, Oxford Biomedica; Richard GaynorPresident & CEO, Neon Therapeutics; Adam GridleyPresident & CEO, Histogenics; Sven KiliVP, Gene Therapy Development Head, GlaxoSmithKline; Gregory LaRosaCSO & SVP, Rare Disease Research, Pfizer; Christopher LooseCo-Founder & CSO, Frequency Therapeutics; Geoff MacKayPresident & CEO, AvroBio; James NobleCEO, Adaptimmune; Stephen PotterCBO, AGTC; Amber SalzmanPresident & CEO, Adverum; Alvin ShihCEO, Enzyvant; J. Craig VenterCo-Founder & Executive Chairman, Human Longevity; Sue WasherPresident & CEO, AGTC; Michael WestCo-CEO, BioTime

Time Agenda
8:00-9:00 am

Registration and Networking Breakfast

9:00-9:15 am

Welcome and Opening Remarks

9:15-9:45 am

2017 Industry Outlook: What's Driving Development in Cell & Gene Therapies?
James Noble
, CEO, Adaptommune; Greg LaRosa, SVP & CSO, Rare Diseases, Pfizer; Alex Pasteur, Partner, F-Prime Capital Partners; Amber Salzmann, President & CEO, Adverum Biotechnologies

9:45-10:15 am

Business Model Efficiencies: Identifying and Overcoming Hurdles
Adam Bruce
, Founder & CEO, TikoMed; Sven Kili, VP, Gene Therapy Development Head, GlaxoSmithKline

10:15-10:35 am

Moderated Keynote
George Church
, Professor of Genetics, Harvard Medical School

10:35-11:05 am

Networking Break

11:05-11:35 am

Maximizing Tech Transfer for Therapeutic Development
Joel Schneider
, Chief Technology Officer, Solid Biosciences
Moderator: Stephen Potter, CBO, AGTC

11:35-12:05 pm

Overcoming Technology Challenges in Cell & Gene Therapy Companies
Chris LooseCo-Founder & CSO, Frequency Therapeutics; Linda McAllister, VP, Scientific Affairs, BD Biosciences; Felicia Pagliuca, Co-Founder & VP, Cell Biology R&D, Semma Therapeutics; Jack Reich, CEO, Renova Therapeutics

 

12:05-12:35 pm

Leveraging Ideal Partnerships in Cell & Gene Therapy
Donna Armentano
, ED, Global Head, Gene Therapy, Pfizer; Lee Buckler, President & CEO, RepliCel Life Sciences; Richard Brudnick, EVP, Corporate Development & Alliance Management, Bioverativ; Olivier Danos, SVP, Cell & Gene Therapy, Biogen

12:35-1:35 pm

Networking Lunch

1:35-2:05 pm

Engaging with Regulators: When and How?
Eric Crombez, CMO, Dimension Therapeutics; Adam Gridley, President & CEO, Histogenics; Alvin Shih, CEO, Enzyvant

2:05-2:35 pm

Streamlining Manufacturing and Delivery Challenges
Geoff MacKay
, President & CEO, AvroBio

2:35-3:05 pm

Financing Innovation: Attracting Investment

3:05-3:35 pm

Networking Break

3:35-3:55 pm

Fireside Chat
J. Craig Venter
, Co-Founder & Executive Chairman, Human Longevity; Michael West, Co-CEO, BioTime
Moderator: David GraingerPartner, Medicxi Ventures

3:55-4:25 pm

Commercial Optimization: Overcoming Hurdles to Market Access
Dominich Colangelo, CEO, Vericel; Al Gianchetti, President & CEO, XyloCor Therapeutics; Mark Rothera, CCO, PTC Therapeutics

4:25-4:55 pm

Outlook on 2018: Trends to Watch
Marc Beer
, Chairman, Minerva Neurosciences; Stephen Russell, CEO, Vyriad

4:55-6:00 pm

Cocktail Reception

Supporting Sponsors: (see all sponsors)

<